Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2a (HIF-2a) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC).
Belzutifan;Pembrolizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2a (HIF-2a) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC). ### Output: Belzutifan;Pembrolizumab